ArticleNeurochemical research2025
Early Dopaminergic Dysfunction Induces PRO-VGF Changes in Blood and Brain of Rats with Alpha-Synuclein Overexpression.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dapagliflozin ameliorates motor deficits in a Parkinson's disease model induced by 6-OHDA: An integrative in vivo and in silico approach from α-synuclein/A2AAR/TH/TNF-α to APAF-1/caspase-3 modulation.Inflammopharmacology · 2026Article
- Effect of α-Synuclein Overexpression on NAPP-129 and TLQP-62 in Rat Brain and Plasma.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous research revealed a reduction in the VGF immunoreactivity within the substantia nigra (SN) of rats with a 60-90% dopaminergic neuron loss and in the plasma of newly diagnosed Parkinson's disease (PD) patients. Hence, our aim was to explore whether central and peripheral proVGF changes occur during early dopaminergic dysfunction. To investigate this, we employed a rat model mimicking early-stage PD by injecting the SN unilaterally with an adeno-associated virus (AAV) carrying either the human α-synuclein (α-syn; n = 19) or green fluorescent protein (GFP; n = 18) gene. After conducting motor assessments and sacrificing the animals, brain and blood samples were collected. Tyrosine hydroxylase (TH)-, glutamic acid decarboxylase (GAD)-, and phosphorylated (p)-α-syn antibodies were used for immunohistochemistry (IHC), while an antibody targeting the C-terminus of proVGF was employed for IHC, western blot (WB), and enzyme linked immunosorbent asssay (ELISA). The α-syn overexpression caused a modest (~ 30%) reduction in TH immunoreactivity within the SN-without affecting the striatum-and did so without producing overt motor symptoms, effectively modeling a pre-symptomatic PD stage. This early dopaminergic dysfunction was accompanied by decreased immunostaining for both proVGF C-trerminus and GAD in the SN, but not the striatum. Reduction in plasma proVGF levels were also observed, indicating systemic changes during initial dopaminergic impairment. Analysis using WB confirmed a decrease in a 70 kDa band consistent with proVGF in both SN and plasma. These findings suggest proVGF as a promising early biomarker for PD, opening new avenues for intervention before the onset of clinical symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.